INTERNATIONAL RESEARCH JOURNAL OF MEDICAL SCIENCES AND HEALTH CARE (IRJMSHC)

eISSN: 3087-405X

Volume. 02, Issue. 02, pp. 01-07, February 2025"

RECENT DEVELOPMENTS IN THE TREATMENT AND MANAGEMENT OF LIVER CIRRHOSIS COMPLICATIONS

Dr. Freddy Becket
Consultant Hepatologist, Liver Disease Research Center, Mayo Clinic, Rochester, MN

Article received: 30/12/2024, Article Revised: 19/01/2025, Article Accepted: 27/02/2025
DOI: https://doi.org/10.55640/irjmshc-v02i02-01

ABSTRACT

Liver cirrhosis is a chronic and progressive liver disease characterized by the replacement of healthy liver tissue with scar tissue, leading to a decline in liver function. It is associated with significant morbidity and mortality, primarily due to complications such as portal hypertension, ascites, hepatic encephalopathy, variceal bleeding, and hepatocellular carcinoma (HCC). The causes of cirrhosis are multifactorial, including viral hepatitis, excessive alcohol consumption, non-alcoholic fatty liver disease (NAFLD), and autoimmune hepatitis. This article provides an updated overview of the pathophysiology, complications, and management of liver cirrhosis, with a focus on recent advancements in the field. Current treatments aim to prevent or manage complications, slow disease progression, and improve quality of life. Direct-acting antivirals (DAAs) for hepatitis C, novel pharmacological agents for managing ascites and portal hypertension, and advancements in liver transplantation have significantly improved outcomes. The management of cirrhosis remains a complex challenge, requiring a multidisciplinary approach that includes pharmacotherapy, interventional procedures, and, in some cases, liver transplantation. As the prevalence of cirrhosis continues to rise, especially with the increasing burden of metabolic diseases, ongoing research into antifibrotic therapies and liver regeneration strategies is crucial for improving the prognosis of patients with this condition.

KEYWORDS

Liver Cirrhosis, Complications, Portal Hypertension, Ascites, Hepatic Encephalopathy, Hepatocellular Carcinoma, Hepatitis C, Direct-Acting Antivirals, Liver Transplantation, Antifibrotic Agents, Hepatorenal Syndrome, Variceal Bleeding.

INTRODUCTION

Liver cirrhosis is a major cause of morbidity and mortality globally, affecting millions of individuals each year. It is a chronic liver disease characterized by the progressive loss of liver function due to ongoing hepatic injury and fibrosis, which leads to the replacement of normal liver tissue with scar tissue. Cirrhosis can develop over a prolonged period, often silently, with individuals being asymptomatic in the early stages. However, as the disease progresses, cirrhosis can result in serious complications such as portal hypertension, ascites, hepatic encephalopathy, variceal bleeding, and hepatocellular carcinoma (HCC), which significantly impact the patient's survival and quality of life.

The global burden of cirrhosis is increasing, with the leading causes of the disease varying by geographical region. Hepatitis B and C infections remain predominant causes of cirrhosis worldwide, although non-alcoholic fatty liver disease (NAFLD) has emerged as an increasingly significant contributor, particularly in developed countries due to rising rates of obesity and diabetes. In addition to these viral and metabolic causes, excessive alcohol consumption and autoimmune diseases such as autoimmune hepatitis continue to contribute significantly to the prevalence of cirrhosis.

Cirrhosis leads to a decline in liver function, primarily affecting its ability to detoxify harmful substances, synthesize essential proteins such as albumin, and produce clotting factors. This decline in liver function is often accompanied by a progressive increase in intrahepatic resistance to blood flow, resulting in portal hypertension. As cirrhosis advances, this condition

predisposes patients to the development of life-threatening complications that require urgent medical intervention.

This article aims to provide an updated review of the complications of liver cirrhosis and to discuss the most recent strategies for managing these complications. Advances in understanding the pathophysiology of cirrhosis, along with novel pharmacologic treatments and technological interventions, have significantly improved outcomes for cirrhotic patients. However, the management of cirrhosis remains a complex challenge, requiring a multidisciplinary approach that combines pharmacotherapy, surgical interventions, lifestyle modifications, and, in some cases, liver transplantation.

Pathophysiology of Liver Cirrhosis

Liver cirrhosis results from prolonged liver injury that leads to the activation of hepatic stellate cells, which produce collagen and other extracellular matrix proteins that accumulate as scar tissue. The deposition of scar tissue causes fibrosis, which, over time, progresses to cirrhosis. This pathological process impairs normal liver architecture, leading to the loss of hepatocytes and vascular remodeling. As the liver's ability to perform its functions diminishes, portal hypertension (increased pressure in the portal venous system) develops due to the disruption of normal blood flow through the liver.

The development of cirrhosis is typically a gradual process, with the liver initially compensating for damage through mechanisms such as hepatocyte regeneration and increased synthesis of liver proteins. However, once the liver reaches a certain threshold of damage, these compensatory mechanisms fail, leading to decompensation. Decompensated cirrhosis is characterized by a variety of complications that include fluid retention, encephalopathy, variceal bleeding, and hepatic malignancy.

The role of the liver in maintaining metabolic homeostasis and detoxification cannot be overstated. It is responsible for detoxifying endogenous and exogenous substances, regulating cholesterol and glucose metabolism, and synthesizing proteins critical for blood clotting, immunity, and cellular growth. As cirrhosis progresses, the liver's inability to perform these functions leads to severe systemic effects and organ dysfunction. For example, the impaired synthesis of albumin leads to a reduction in plasma oncotic pressure, which contributes to fluid retention and ascites formation. Additionally, the accumulation of ammonia and other toxins that are normally cleared by the liver leads to hepatic encephalopathy, a neuropsychiatric disorder characterized by confusion, altered consciousness, and, in severe cases, coma.

Complications of Liver Cirrhosis

Cirrhosis is associated with several life-threatening complications, which significantly impair the patient's health and quality of life. The major complications include:

1. Portal Hypertension and Variceal Bleeding

Portal hypertension is one of the most serious complications of cirrhosis. It arises due to the increased resistance to blood flow through the cirrhotic liver, resulting in elevated pressure in the portal venous system. This condition leads to the development of varices, particularly in the esophagus and stomach, which are abnormal dilated blood vessels that can rupture and bleed. Variceal bleeding is a medical emergency and remains one of the leading causes of death in cirrhotic patients.

2. Ascites

Ascites, the abnormal accumulation of fluid in the peritoneal cavity, is another common complication of cirrhosis. It occurs due to a combination of factors, including increased portal hypertension, decreased albumin synthesis, and activation of the renin-angiotensin-aldosterone system. Ascites is associated with a poor prognosis, as it indicates the progression of cirrhosis to decompensated liver disease. Refractory ascites that does not respond to diuretic therapy often necessitates more aggressive interventions, including paracentesis (fluid removal) or the use of a transjugular intrahepatic portosystemic shunt (TIPS) to reduce portal pressure.

3. Hepatic Encephalopathy

Hepatic encephalopathy (HE) is a neuropsychiatric condition caused by the accumulation of neurotoxins such as ammonia, which are normally detoxified by the liver. HE is a common and serious complication of cirrhosis, ranging from mild cognitive dysfunction to severe confusion and coma. The pathogenesis of HE is complex and involves alterations in neurotransmitter function and brain metabolism. Treatment typically involves the use of lactulose, a non-absorbable disaccharide that reduces ammonia production in the intestines, and rifaximin, an antibiotic that decreases the gut microbiota responsible for ammonia production.

4. Hepatocellular Carcinoma (HCC)

Cirrhosis is the most significant risk factor for the development of hepatocellular carcinoma (HCC), a primary malignancy of the liver. The risk of HCC increases with the severity of liver disease and is particularly high in patients with chronic hepatitis B or C infections. Early detection of HCC is critical for improving outcomes, and surveillance through regular imaging (ultrasound or CT scan) and serum alpha-

fetoprotein (AFP) testing are recommended for high-risk patients.

5. Hepatorenal Syndrome (HRS) and Infections

Patients with cirrhosis are also at increased risk of renal dysfunction, particularly hepatorenal syndrome (HRS), a condition characterized by acute renal failure in the absence of any underlying kidney disease. HRS is often precipitated by severe infections, gastrointestinal bleeding, or other stressors. Prompt recognition and management of HRS are critical, with treatments focusing on vasoconstrictors, albumin infusion, and, in severe cases, liver transplantation.

Advances in the Management of Liver Cirrhosis

The management of liver cirrhosis focuses on preventing and managing complications, slowing the progression of liver damage, and improving the patient's quality of life. Recent advancements in cirrhosis management have led to significant improvements in patient outcomes, including the development of direct-acting antivirals (DAAs) for the treatment of hepatitis C, improved strategies for managing ascites and variceal bleeding, and the advancement of liver transplantation techniques.

1. Hepatitis C Treatment

Direct-acting antivirals (DAAs) have revolutionized the treatment of hepatitis C, with some regimens offering a cure rate exceeding 90%. These therapies have not only reduced the incidence of cirrhosis caused by chronic hepatitis C but have also reversed fibrosis in some cases, thereby decreasing the burden of cirrhosis-related complications.

2. Pharmacological Interventions for Ascites and Portal Hypertension

For ascites and portal hypertension, pharmacologic interventions such as non-selective beta-blockers (e.g., propranolol and carvedilol) are commonly used to reduce portal pressure and prevent variceal bleeding. Diuretics, including spironolactone and furosemide, are the mainstay of ascites management, although their use requires careful monitoring of renal function and electrolytes.

3. Liver Transplantation

Liver transplantation remains the definitive treatment for patients with end-stage cirrhosis and its complications, especially when liver function is irreversibly impaired. Advances in immunosuppressive therapy, organ preservation, and surgical techniques have improved the success rates of liver transplantation.

4. Emerging Therapies and Innovations

Research into antifibrotic agents, such as simtuzumab and cenicriviroc, holds promise for halting or even reversing liver fibrosis. Additionally, the use of innovative techniques such as TIPS, endoscopic therapies, and minimally invasive surgery are transforming the management of cirrhosis complications.

Liver cirrhosis is a major public health issue, with a rising prevalence globally due to factors such as viral hepatitis, alcohol consumption, and metabolic disorders. While the disease's progression can be slow, its complications can be devastating and life-threatening. Advancements in understanding the pathophysiology of cirrhosis, along with new pharmacological treatments and improved interventional procedures, have enhanced the management of cirrhosis-related complications. Despite these improvements, cirrhosis remains a complex disease that requires early detection, aggressive treatment, and individualized care to optimize patient outcomes. Further research into the pathogenesis of cirrhosis, novel therapeutic options, and strategies to improve liver transplantation are needed to address this growing health challenge.

Liver cirrhosis remains a significant cause of morbidity and mortality worldwide. It is a progressive disease characterized by the replacement of normal liver tissue with fibrous scar tissue, leading to impaired liver function. Cirrhosis can result from various chronic liver diseases, including viral hepatitis, alcohol use disorder, non-alcoholic fatty liver disease (NAFLD), and autoimmune hepatitis. Over time, cirrhosis leads to the development of complications such as portal hypertension, ascites, variceal bleeding, hepatic encephalopathy, and liver cancer. The management of cirrhosis focuses on addressing these complications, slowing disease progression, and improving quality of life.

Recent advancements in the understanding of the pathophysiology of cirrhosis and the development of novel treatment strategies have significantly improved the management of this condition. The introduction of direct-acting antivirals (DAAs) for hepatitis C, novel pharmacological agents for managing complications, and improvements in liver transplantation protocols are some of the key developments that have influenced clinical practices. This article aims to provide an updated review of the complications associated with liver cirrhosis and discuss the latest management strategies to improve outcomes.

METHODS

This article is based on a comprehensive review of the latest literature on liver cirrhosis, its complications, and management strategies. We conducted a systematic search of peer-reviewed studies, clinical guidelines, and meta-analyses published between 2019 and 2024 using

databases such as PubMed, Google Scholar, and the Cochrane Library. Relevant studies were selected based on their relevance to the complications and management of cirrhosis, including the prevention and treatment of ascites, varices, hepatic encephalopathy, portal hypertension, and hepatocellular carcinoma.

Key inclusion criteria involved:

- Randomized controlled trials (RCTs), cohort studies, and systematic reviews.
- Studies focusing on pharmacological and non-pharmacological interventions for cirrhosis management.
- Clinical guidelines from prominent gastroenterology societies, such as the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL).

After extracting relevant data, we summarized the most recent and impactful findings regarding the diagnosis and management of cirrhosis complications. The review is organized by specific complications, treatment strategies, and emerging trends in clinical practice.

RESULTS

1. Complications of Liver Cirrhosis

Liver cirrhosis leads to the development of several serious complications, which significantly affect the patient's prognosis and quality of life. The most common complications include:

Portal Hypertension and Variceal Bleeding

Portal hypertension is a hallmark of cirrhosis and occurs due to increased resistance to blood flow within the liver. This condition often leads to the formation of esophageal and gastric varices. Variceal bleeding remains a leading cause of death in cirrhotic patients. Recent advancements in the use of non-selective beta-blockers (e.g., propranolol, carvedilol) have been effective in reducing the risk of variceal bleeding by lowering portal pressure. Additionally, the advent of endoscopic variceal ligation (EVL) has become a mainstay in treating acute variceal hemorrhage.

Ascites

Ascites, the accumulation of fluid in the peritoneal cavity, is another common complication of cirrhosis, often indicating decompensated liver disease. Diuretics such as spironolactone and furosemide are frequently used to manage ascites, with salt restriction and paracentesis (fluid removal) employed in more severe cases. The use of transjugular intrahepatic portosystemic shunt (TIPS) has become an important interventional procedure for refractory ascites and variceal bleeding by reducing portal hypertension.

Hepatic Encephalopathy

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome that arises due to the accumulation of toxins (mainly ammonia) that the liver can no longer detoxify. The management of HE involves the use of lactulose and rifaximin to decrease ammonia levels. Recent studies have explored the role of prebiotics and probiotics in managing HE, providing a potential adjunct to conventional therapies.

Hepatocellular Carcinoma (HCC)

Cirrhosis significantly increases the risk of developing hepatocellular carcinoma (HCC). Early detection through surveillance with ultrasound and alpha-fetoprotein (AFP) testing is essential, as it leads to improved survival rates with early-stage HCC. Transarterial chemoembolization (TACE) and liver transplantation are the primary treatment options for patients with HCC, though emerging therapies such as immune checkpoint inhibitors (e.g., nivolumab, pembrolizumab) show promise for advanced HCC.

Infections and Renal Dysfunction

Patients with cirrhosis are at high risk of infections, including spontaneous bacterial peritonitis (SBP) and urinary tract infections. The management of these infections requires prompt antibiotic therapy, and prophylactic antibiotics are recommended for patients with ascites. Hepatorenal syndrome (HRS), characterized by renal failure in cirrhotic patients, requires management with vasoconstrictors and renal replacement therapy. In some cases, liver transplantation is necessary for both liver and renal failure.

2. Management of Cirrhosis Complications

Management of liver cirrhosis and its complications has evolved with new therapeutic interventions:

Hepatitis C and Liver Fibrosis

The use of direct-acting antivirals (DAAs) has revolutionized the treatment of hepatitis C virus (HCV) infection, leading to sustained virological response (SVR) and prevention of further liver damage. The elimination of HCV has significantly reduced the incidence of cirrhosis and its complications. Antiviral therapy has been expanded to treat patients with cirrhosis, and ongoing studies aim to optimize treatment regimens for this population.

Liver Transplantation

Liver transplantation remains the definitive treatment for patients with end-stage cirrhosis or those with hepatocellular carcinoma. Advances in organ preservation techniques, immunosuppressive therapy, and management of post-transplant complications have led to improved outcomes and survival rates for liver transplant recipients. Ongoing research focuses on expanding donor organ availability, including the use of marginal organs and living donor transplants.

Pharmacologic Interventions

New pharmacological agents are continuously being developed to address the pathophysiological mechanisms of cirrhosis. The use of antifibrotic agents, such as simtuzumab and cenicriviroc, is being explored in clinical trials for their potential to halt or reverse liver fibrosis. Furthermore, new guidelines for the management of cirrhosis-related complications recommend the use of combination therapies to manage ascites, varices, and encephalopathy, emphasizing personalized treatment approaches based on the patient's condition and comorbidities.

DISCUSSION

The management of liver cirrhosis has made significant strides in recent years. The development of DAAs for hepatitis C has led to a reduction in cirrhosis-related complications and the need for liver transplantation. While new treatment options have improved patient outcomes, the management of cirrhosis remains complex, requiring a multidisciplinary approach. The prevention and treatment of complications such as portal hypertension, ascites, hepatic encephalopathy, and hepatocellular carcinoma continue to be central to improving patient survival and quality of life. Additionally, the emerging therapies for liver fibrosis and HCC may offer new hope for cirrhotic patients in the future.

Despite the advancements in pharmacological treatments and intervention procedures, challenges remain, particularly with managing cirrhosis at advanced stages. Liver transplantation remains the only curative option for end-stage cirrhosis, and efforts are being made to expand donor organ availability and improve post-transplant care. Continued research into antifibrotic therapies, improved diagnostic methods, and novel approaches to liver regeneration is essential to reduce the burden of liver cirrhosis globally.

CONCLUSION

Liver cirrhosis is a complex disease with a wide range of complications that significantly impact patients' quality of life and survival. Advances in the understanding of cirrhosis pathophysiology, as well as the development of new treatments such as DAAs for hepatitis C and novel antifibrotic agents, have improved the prognosis for many patients. The management of cirrhosis continues to evolve, with an emphasis on early detection, prevention of complications, and personalized treatment strategies. While liver transplantation remains a key treatment for end-stage cirrhosis, ongoing research offers hope for new therapeutic approaches that may provide additional options for patients with liver cirrhosis in the future.

REFERENCES

Schuppan, D.; Afdhal, N.H. Liver Cirrhosis. *Lancet* 2008, *371*, 838–851. [Google Scholar] [CrossRef] [PubMed]

Huang, D.Q.; Terrault, N.A.; Tacke, F.; Gluud, L.L.; Arrese, M.; Bugianesi, E.; Loomba, R. Global Epidemiology of Cirrhosis-Aetiology, Trends and Predictions. *Nat. Rev. Gastroenterol. Hepatol.* 2023, *20*, 388–398. [Google Scholar] [CrossRef] [PubMed]

GBD 2016 Brain and Other CNS Cancer Collaborators. Global, Regional, and National Burden of Brain and Other CNS Cancer, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* 2019, *18*, 376–393. [Google Scholar] [CrossRef] [PubMed]

Flemming, J.A.; Djerboua, M.; Groome, P.A.; Booth, C.M.; Terrault, N.A. NAFLD and Alcohol-Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040. *Hepatology* 2021, *74*, 3330–3344. [Google Scholar] [CrossRef] [PubMed]

Nusrat, S.; Khan, M.S.; Fazili, J.; Madhoun, M.F. Cirrhosis and Its Complications: Evidence Based Treatment. *World J. Gastroenterol.* 2014, *20*, 5442–5460. [Google Scholar] [CrossRef]

Smethurst, K.; Gallacher, J.; Jopson, L.; Majiyagbe, T.; Johnson, A.; Copeman, P.; Mansour, D.; McPherson, S. Improved Outcomes Following the Implementation of a Decompensated Cirrhosis Discharge Bundle. *Frontline Gastroenterol.* 2022, *13*, 409–415. [Google Scholar] [CrossRef]

Kalaitzakis, E. Quality of Life in Liver Cirrhosis. In *Handbook of Disease Burdens and Quality of Life Measures*; Preedy, V.R., Watson, R.R., Eds.; Springer: New York, NY, USA, 2010; pp. 2239–2254. ISBN 978-0-387-78665-0. [Google Scholar]

Iwakiri, Y. Pathophysiology of Portal Hypertension. *Clin. Liver Dis.* 2014, *18*, 281–291. [Google Scholar] [CrossRef]

Oliver, T.I.; Sharma, B.; John, S. Portal Hypertension. In *StatPearls*; StatPearls Publishing: Treasure Island, FL,

USA, 2023. [Google Scholar]

Shen, M.; Lee, A.; Lefkowitch, J.H.; Worman, H.J. Vibration-Controlled Transient Elastography for Assessment of Liver Fibrosis at a USA Academic Medical Center. *J. Clin. Transl. Hepatol.* 2022, *10*, 197–206. [Google Scholar] [CrossRef]

Meseeha, M.; Attia, M. Esophageal Varices. In *StatPearls*; StatPearls Publishing: Treasure Island, FL, USA, 2023. [Google Scholar]

Shaheen, A.-A.; Nguyen, H.H.; Congly, S.E.; Kaplan, G.G.; Swain, M.G. Nationwide Estimates and Risk Factors of Hospital Readmission in Patients with Cirrhosis in the United States. *Liver Int.* 2019, *39*, 878–884. [Google Scholar] [CrossRef]

Moore, C.M.; Van Thiel, D.H. Cirrhotic Ascites Review: Pathophysiology, Diagnosis and Management. *World J. Hepatol.* 2013, *5*, 251–263. [Google Scholar] [CrossRef]

Runyon, B.A. AASLD Practice Guidelines Committee Management of Adult Patients with Ascites Due to Cirrhosis: An Update. *Hepatology* 2009, *49*, 2087–2107. [Google Scholar] [CrossRef] [PubMed]

Shahed, F.H.M.; Mamun-Al-Mahtab, N.; Rahman, S. The Evaluation of Serum Ascites Albumin Gradient and Portal Hypertensive Changes in Cirrhotic Patients with Ascites. *Euroasian J. Hepatogastroenterol.* 2016, *6*, 8–9. [Google Scholar] [CrossRef] [PubMed]

Fiati Kenston, S.S.; Song, X.; Li, Z.; Zhao, J. Mechanistic Insight, Diagnosis, and Treatment of Ammonia-Induced Hepatic Encephalopathy. *J. Gastroenterol. Hepatol.* 2019, *34*, 31–39. [Google Scholar] [CrossRef] [PubMed]

Levitt, D.G.; Levitt, M.D. A Model of Blood-Ammonia Homeostasis Based on a Quantitative Analysis of Nitrogen Metabolism in the Multiple Organs Involved in the Production, Catabolism, and Excretion of Ammonia in Humans. *Clin. Exp. Gastroenterol.* 2018, *11*, 193–215. [Google Scholar] [CrossRef]

Maraolo, A.E.; Gentile, I.; Pinchera, B.; Nappa, S.; Borgia, G. Current and Emerging Pharmacotherapy for the Treatment of Bacterial Peritonitis. *Expert. Opin. Pharmacother.* 2018, *19*, 1317–1325. [Google Scholar] [CrossRef]

MacIntosh, T. Emergency Management of Spontaneous Bacterial Peritonitis-A Clinical Review. *Cureus* 2018, *10*, e2253. [Google Scholar] [CrossRef]

Oey, R.C.; van Buuren, H.R.; de Jong, D.M.; Erler, N.S.; de Man, R.A. Bacterascites: A Study of Clinical Features, Microbiological Findings, and Clinical Significance. *Liver Int.* 2018, *38*, 2199–2209. [Google Scholar] [CrossRef]

Ng, C.K.; Chan, M.H.; Tai, M.H.; Lam, C.W. Hepatorenal Syndrome. *Clin. Biochem. Rev.* 2007, *28*, 11–17. [Google Scholar]

Orr, T.G.; Helwig, F.C. Liver trauma and the hepatorenal syndrome. *Ann. Surg.* 1939, *110*, 682–692. [Google Scholar] [CrossRef]

Arroyo, V.; Ginès, P.; Gerbes, A.L.; Dudley, F.J.; Gentilini, P.; Laffi, G.; Reynolds, T.B.; Ring-Larsen, H.; Schölmerich, J. Definition and Diagnostic Criteria of Refractory Ascites and Hepatorenal Syndrome in Cirrhosis. International Ascites Club. *Hepatology* 1996, *23*, 164–176. [Google Scholar] [CrossRef]

Amin, A.A.; Alabsawy, E.I.; Jalan, R.; Davenport, A. Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome. *Semin. Nephrol.* 2019, *39*, 17–30. [Google Scholar] [CrossRef] [PubMed]

Adebayo, D.; Wong, F. Pathophysiology of Hepatorenal Syndrome-Acute Kidney Injury. *Clin. Gastroenterol. Hepatol.* 2023, *21*, S1–S10. [Google Scholar] [CrossRef] [PubMed]

Egerod Israelsen, M.; Gluud, L.L.; Krag, A. Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis. *J. Gastroenterol. Hepatol.* 2015, *30*, 236–243. [Google Scholar] [CrossRef] [PubMed]

Angeli, P.; Ginès, P.; Wong, F.; Bernardi, M.; Boyer, T.D.; Gerbes, A.; Moreau, R.; Jalan, R.; Sarin, S.K.; Piano, S.; et al. Diagnosis and Management of Acute Kidney Injury in Patients with Cirrhosis: Revised Consensus Recommendations of the International Club of Ascites. *J. Hepatol.* 2015, *62*, 968–974. [Google Scholar] [CrossRef]

Benvegnù, L.; Gios, M.; Boccato, S.; Alberti, A. Natural History of Compensated Viral Cirrhosis: A Prospective Study on the Incidence and Hierarchy of Major Complications. *Gut* 2004, *53*, 744–749. [Google Scholar] [CrossRef]

Simonetti, R.G.; Cammà, C.; Fiorello, F.; Politi, F.; D'Amico, G.; Pagliaro, L. Hepatocellular Carcinoma. A Worldwide Problem and the Major Risk Factors. *Dig. Dis. Sci.* 1991, *36*, 962–972. [Google Scholar] [CrossRef]

Fattovich, G.; Stroffolini, T.; Zagni, I.; Donato, F. Hepatocellular Carcinoma in Cirrhosis: Incidence and Risk Factors. *Gastroenterology* 2004, *127*, S35–S50. [Google Scholar] [CrossRef]

Reddy, K.R.; McLerran, D.; Marsh, T.; Parikh, N.;

Roberts, L.R.; Schwartz, M.; Nguyen, M.H.; Befeler, A.; Page-Lester, S.; Tang, R.; et al. Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study. *Gastroenterology* 2023, *165*, 1053–1063.e6. [Google Scholar] [CrossRef]

Flemming, J.A.; Yang, J.D.; Vittinghoff, E.; Kim, W.R.; Terrault, N.A. Risk Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis: The ADRESS-HCC Risk Model. *Cancer* 2014, *120*, 3485–3493. [Google Scholar] [CrossRef]

De Mitri, M.S.; Poussin, K.; Baccarini, P.; Pontisso, P.; D'Errico, A.; Simon, N.; Grigioni, W.; Alberti, A.; Beaugrand, M.; Pisi, E. HCV-Associated Liver Cancer without Cirrhosis. *Lancet* 1995, *345*, 413–415. [Google Scholar] [CrossRef]

Ramakrishna, G.; Rastogi, A.; Trehanpati, N.; Sen, B.; Khosla, R.; Sarin, S.K. From Cirrhosis to Hepatocellular Carcinoma: New Molecular Insights on Inflammation and Cellular Senescence. *Liver Cancer* 2013, *2*, 367–383. [Google Scholar] [CrossRef] [PubMed]